Form4insider filings, from the source

SEC Form 4 · accession 0001708138-17-000011

REGENERON PHARMACEUTICALS, INC. · REGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Michael S Aberman
Officer — SVP Strategy Investor Relation
Period of report
Jun 21, 2017
Accepted (ET)
Jun 23, 2017 · 4:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockJun 21, 2017M4,500$30.63A9,193D
Common StockJun 21, 2017F270$510.02D8,923D
Common StockJun 21, 2017F1,961$510.02D6,962D
Common StockF2Jun 22, 2017S395$525.21D6,567D
Common StockJun 22, 2017S100$526.02D6,467D
Common StockJun 22, 2017S100$529.61D6,367D
Common StockJun 22, 2017S100$530.66D6,267D
Common StockF3Jun 22, 2017S274$531.51D5,993D
Common StockF4Jun 22, 2017S200$532.27D5,793D
Common StockF5Jun 22, 2017S200$533.48D5,593D
Common StockF6Jun 22, 2017S200$534.51D5,393D
Common StockF7Jun 22, 2017S400$536.52D4,993D
Common StockJun 22, 2017S100$537.50D4,893D
Common StockJun 22, 2017S100$538.30D4,793D
Common StockJun 22, 2017S100$541.00D4,693D
Common Stockholding———11,805Iby GRAT
Common Stockholding———448IBy 401(k) Plan

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Non-Qualified Stock Option (right to buy)F8$30.63Jun 21, 2017M4,500D—Dec 14, 2020Common Stock4,5003,000D

Explanation of responses